Immunic (NASDAQ:IMUX) Rating Increased to Hold at StockNews.com

Immunic (NASDAQ:IMUX) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

Several other equities analysts also recently weighed in on the company. D. Boral Capital reissued a “buy” rating and set a $17.00 price target on shares of Immunic in a research report on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Immunic in a research report on Friday, February 21st. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Immunic presently has an average rating of “Buy” and a consensus price target of $12.67.

Immunic Stock Performance

NASDAQ:IMUX traded up $0.06 during mid-day trading on Wednesday, hitting $1.16. 482,325 shares of the company’s stock traded hands, compared to its average volume of 943,320. The firm’s 50 day simple moving average is $1.05 and its 200 day simple moving average is $1.23. The company has a market cap of $104.49 million, a PE ratio of -0.94 and a beta of 1.89. Immunic has a 1 year low of $0.92 and a 1 year high of $2.11.

Institutional Trading of Immunic

A number of hedge funds have recently added to or reduced their stakes in IMUX. Invesco Ltd. acquired a new position in shares of Immunic during the 4th quarter valued at about $37,000. Virtu Financial LLC purchased a new stake in Immunic in the third quarter valued at approximately $50,000. HB Wealth Management LLC purchased a new stake in Immunic in the fourth quarter valued at approximately $81,000. Barclays PLC acquired a new position in Immunic during the fourth quarter worth approximately $84,000. Finally, Jane Street Group LLC raised its stake in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. 51.82% of the stock is owned by institutional investors and hedge funds.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.